Chemistry:Cannabidiol (medication)
| File:Epidiolex packaging.png US packaging, 2018 | |
| Clinical data | |
|---|---|
| Trade names | Epidiolex, Epidyolex |
Cannabidiol solution may be used as a medication as is sold under the brand name Epidiolex among others. It is taken by mouth. It was approved for medical use in the United States in June 2018 for treatment of two rare forms of childhood epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.[1] Cannabidiol is the first United States Food and Drug Administration (FDA)-approved drug derived from the Cannabis plant.[1][2] It is made by GW Pharmaceuticals. In September 2018, Epidiolex was placed by the United States Drug Enforcement Administration (DEA) in Schedule V, the least restrictive schedule for controlled substances, notwithstanding Cannabis itself being in Schedule I of the Controlled Substances Act, for substances with "no currently accepted medical use".[3][4][5]
In the European Union it is sold as Epidyolex.[6]
The DEA's rescheduling any substance related to Cannabis was considered a "landmark" and "the first time in 46 years that [the DEA] has shifted its stance on a marijuana compound".[5]
References
- ↑ 1.0 1.1 "FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy". US Food and Drug Administration (FDA). June 25, 2018. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms. Retrieved April 21, 2020. "This is the first FDA-approved drug that contains a purified drug substance derived from marijuana."
- ↑ Julia Kollewe (25 June 2018), "UK epilepsy drug to become first cannabis-based medicine in US", The Guardian (Manchester, UK), https://amp.theguardian.com/business/2018/jun/25/uk-epilepsy-drug-set-to-be-first-cannabis-based-medicine-on-us-market
- ↑ "FDA-approved drug Epidiolex placed in schedule V of Controlled Substance Act". Drug Enforcement Administration. September 27, 2018. https://www.dea.gov/press-releases/2018/09/27/fda-approved-drug-epidiolex-placed-schedule-v-controlled-substance-act.
- ↑ Angelica LaVito (September 27, 2018). "DEA reschedules Epidiolex, marijuana-derived drug, paving the way for it to hit the market". CNBC. https://www.cnbc.com/2018/09/27/dea-schedules-epidiolex-allowing-gw-pharma-to-start-selling-the-drug.html.
- ↑ 5.0 5.1 Erin Brodwin (September 27, 2018). "A drug derived from marijuana has triggered the first federal shift on cannabis in half a century, and experts predict an avalanche effect". Business Insider. https://www.businessinsider.com/marijuana-epilepsy-drug-approved-dea-cbd-2018-9.
- ↑ Clifford, Tyler (25 September 2019). "GW Pharma to launch first CBD-based epilepsy drug in Europe 'over the next year or two,' CEO says" (in en). CNBC. https://www.cnbc.com/2019/09/24/ceo-says-gw-pharma-will-launch-first-cbd-based-drug-in-europe.html. Retrieved 29 May 2020.
Further reading
- Abu-Sawwa R, Stehling C. (2020). "Epidiolex (Cannabidiol) Primer: Frequently Asked Questions for Patients and Caregivers.". J Pediatr Pharmacol Ther. 25 (1). doi:10.5863/1551-6776-25.1.75.
External links
 |
